On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
Some of the best links we picked up around the internet
Researchers in Japan have developed a CRISPR-Cas-based system to edit epigenetic marks in mouse sperm, enabling direct investigation of whether DNA...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
American researchers have developed an RNA-based platform that uses CRISPR epigenetic editors to durably silence or activate genes in primary human T...
Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...
